These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 17319461)

  • 21. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice.
    Belin de Chantemèle EJ; Mintz JD; Rainey WE; Stepp DW
    Hypertension; 2011 Aug; 58(2):271-9. PubMed ID: 21690486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms mediating renal sympathetic nerve activation in obesity-related hypertension.
    Chen W; Leo S; Weng C; Yang X; Wu Y; Tang X
    Herz; 2015 Apr; 40 Suppl 2():190-6. PubMed ID: 24609799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in baroreflex control of renal sympathetic nerve activity in high-fat-fed rats as a predictor of hypertension.
    Fardin NM; Oyama LM; Campos RR
    Obesity (Silver Spring); 2012 Aug; 20(8):1591-7. PubMed ID: 22257982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity, kidney dysfunction and hypertension: mechanistic links.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Nat Rev Nephrol; 2019 Jun; 15(6):367-385. PubMed ID: 31015582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits.
    Lim K; Burke SL; Head GA
    Hypertension; 2013 Mar; 61(3):628-34. PubMed ID: 23339171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary hypertension: obesity and the metabolic syndrome.
    Singer GM; Setaro JF
    J Clin Hypertens (Greenwich); 2008 Jul; 10(7):567-74. PubMed ID: 18607142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leptin, Obesity, and Hypertension: A Review of Pathogenetic Mechanisms.
    Lu SC; Akanji AO
    Metab Syndr Relat Disord; 2020 Nov; 18(9):399-405. PubMed ID: 32876506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction in resting metabolic rate and ratio of plasma leptin to urinary nitric oxide: influence on obesity-related hypertension.
    Golan E; Tal B; Dror Y; Korzets Z; Vered Y; Weiss E; Bernheim J
    Isr Med Assoc J; 2002 Jun; 4(6):426-30. PubMed ID: 12073415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hypertension in obese patients: Pathophysiology and management].
    Girerd X; Hansel B
    Presse Med; 2009 Apr; 38(4):609-13. PubMed ID: 19233604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 31. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of selective leptin resistance in diet-induced obesity hypertension.
    Rahmouni K; Morgan DA; Morgan GM; Mark AL; Haynes WG
    Diabetes; 2005 Jul; 54(7):2012-8. PubMed ID: 15983201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity-hypertension: emerging concepts in pathophysiology and treatment.
    Mathew B; Patel SB; Reams GP; Freeman RH; Spear RM; Villarreal D
    Am J Med Sci; 2007 Jul; 334(1):23-30. PubMed ID: 17630587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the obesity epidemic on hypertension and renal disease.
    Hall JE; Jones DW; Kuo JJ; da Silva A; Tallam LS; Liu J
    Curr Hypertens Rep; 2003 Oct; 5(5):386-92. PubMed ID: 12948431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of hypertension and kidney disease in obesity.
    Hall JE; Brands MW; Henegar JR
    Ann N Y Acad Sci; 1999 Nov; 892():91-107. PubMed ID: 10842655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The concept of selective leptin resistance: evidence from agouti yellow obese mice.
    Correia ML; Haynes WG; Rahmouni K; Morgan DA; Sivitz WI; Mark AL
    Diabetes; 2002 Feb; 51(2):439-42. PubMed ID: 11812752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Sympathetic nervous system, plasma volume, and hypertension.
    Christensen NJ
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21188813
    [No Abstract]   [Full Text] [Related]  

  • 38. Leptin and the central neural mechanisms of obesity hypertension.
    Rahmouni K; G Haynes W
    Drugs Today (Barc); 2002 Dec; 38(12):807-17. PubMed ID: 12582470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension and obesity.
    Aneja A; El-Atat F; McFarlane SI; Sowers JR
    Recent Prog Horm Res; 2004; 59():169-205. PubMed ID: 14749502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurobiology of human obesity.
    Eikelis N; Esler M
    Exp Physiol; 2005 Sep; 90(5):673-82. PubMed ID: 16105936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.